Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients - Wikidata - awgldk - TriplyDB

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

http://www.wikidata.org/entity/Q35585366

about

Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis New and emerging disease modifying therapies for multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Atacicept: targeting B cells in multiple sclerosis B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis The Ins and Outs of B Cells in Multiple Sclerosis Hypersensitivity Responses in the Central Nervous System Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments Gut commensalism, cytokines, and central nervous system demyelination Humoral-targeted immunotherapies in multiple sclerosis Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics Neuroinflammation: Ways in Which the Immune System Affects the Brain Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies Monoclonal antibodies and progressive multifocal leukoencephalopathy Alternative splicing and transcriptome profiling of experimental autoimmune encephalomyelitis using genome-wide exon arrays.The potential utility of B cell-directed biologic therapy in autoimmune diseases.Evans syndrome associated with sterile inflammation of the central nervous system: a case report Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab.Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.Practical considerations on the use of rituximab in autoimmune neurological disorders Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space.Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.

P2860

Q21129427-B387D2CC-E936-4871-85C4-204A70C5DE42 Q21144285-99A5B0F7-9766-410B-BAA2-4CA7424160F1 Q22242305-EB1785EF-ABB8-4915-A489-572E492820F6 Q24201928-16FF9D43-ED7F-4A1F-B30B-E30B41D14853 Q24234454-6281B44A-2343-4696-B2FA-72628CCB0EFF Q24234742-5238E817-12EE-418E-B5C5-C747DE2087D7 Q24628925-E515B823-3705-440C-8FC0-B7F65DFCF46F Q26770664-E3457DE1-AC41-4C6F-A96F-452304963CC0 Q26771459-BD00650F-2B71-48B1-BB37-888002EDB65A Q26776542-D8ABA5D5-F767-42DC-B409-8CA6A219C26C Q26779177-E671835E-7D6B-4908-B1E2-9717C3327477 Q26779416-15C1666B-B4E8-44B6-87CA-0EAFEE0CC8FE Q26822247-4499236C-93AE-4212-88EB-2F8E6F6F136B Q26823444-C39BEAFF-DDE8-4A9C-AB5E-BC9218EFE77F Q26851694-CCF67B66-510C-4CEF-8845-01045B5F8554 Q26863405-156FB93E-0EAE-41F4-8DF3-1F406F6E9F80 Q26865971-E7E97DDE-AB75-4369-89B1-898EEEC3BB3D Q26998412-DEC927EB-569E-49EE-8FA9-262E09569E97 Q28080620-195A01A3-6286-476F-BC2A-B83A828738D8 Q28084055-C1178703-2B0F-4FA2-A951-193379D7BF6E Q28270413-0BC8E1B1-2840-424E-9D65-F1187648966B Q30886149-0FC35C60-EA29-4971-B4B7-F1652844FAFC Q33377109-825FC517-22C0-41D3-8C71-8FC9994537CA Q33411857-08182D45-EEE3-43E8-B967-DD46BB57A5FE Q33692520-D84268A5-E43A-41DF-82A6-052DDB8B5300 Q33802186-0948B432-D246-4A03-8324-4B21880C9808 Q33849373-D9830688-841B-4382-BD35-3EE65DF9527F Q33899917-9ED31A0A-4DAC-45BA-94FB-7E1F5CE4AF73 Q34052870-145C25A6-F36B-449B-9CB0-D5EA2E1A5CD5 Q34132081-62654B8F-5033-40D3-A645-D545088B37FB Q34251673-DF8F4977-2AD2-4A96-A786-B57A254AF827 Q34373452-EA72FA41-C25F-4F2B-876A-70F722F2BA10 Q34409273-B2788CBB-BCA6-4559-A53D-F374D190DBB0 Q34409447-36C26EF7-B34F-4016-8D30-876EEBE8E4CE Q34449329-E8DBCD0A-CF9B-4196-B6B5-9593FB92DC42 Q34504952-4AD6263E-D259-4130-A35E-8D3D24EA420B Q34773444-CE2225DD-8887-4873-8316-403EFA38EDB7 Q34792090-8C4069E7-E049-4E50-98A6-40BF7AF90166 Q34909225-B47BBDC7-8E72-4D29-9741-6A7538D09F87 Q35077861-33D2EA61-FA4E-4F25-B501-069BEF012BEA

P2860

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

http://www.wikidata.org/entity/Q35585366

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Rituximab reduces B cells and ...... of multiple sclerosis patients

@ast

Rituximab reduces B cells and ...... of multiple sclerosis patients

@en

type

label

Rituximab reduces B cells and ...... of multiple sclerosis patients

@ast

Rituximab reduces B cells and ...... of multiple sclerosis patients

@en

prefLabel

Rituximab reduces B cells and ...... of multiple sclerosis patients

@ast

Rituximab reduces B cells and ...... of multiple sclerosis patients

@en

P1433

Q35585366-15374D32-AAA8-481D-9AF7-5A52F3CEBEF4

P1476

Q35585366-C7871851-0134-4884-B440-969697A2D176

P2093

Q35585366-5168BB23-96BA-492E-AB02-FCB97CAE11B0

Q35585366-5ED0EB7F-D4D6-4B55-A157-A3FB9C11DD58

Q35585366-D257F3A7-36F8-4F57-A21F-911060E7581B

Q35585366-E52FD263-A7F5-4DE2-AB51-A26811C44947

P2860

Q35585366-03F31D6B-F878-42EA-9C48-5CA55D29508F

Q35585366-10FB7816-07D7-4FC0-AB8A-DB4A74E6F954

Q35585366-13B1D56E-4902-4948-98D3-C757CC2937EB

Q35585366-31CB2973-6C7D-4C6B-A786-E509BB064AF6

Q35585366-37108E45-D33D-407B-92F2-4CC75B35FE7A

Q35585366-41E0D3FA-E7A7-4208-A82E-A8B3EDB94B14

Q35585366-4CD2A32E-4015-48D7-9C3A-BCF465F549A8

Q35585366-4E9E722A-6C8F-4628-9C93-E223B154AA13

Q35585366-535CF7F5-EB42-435A-977D-DB7AE9F2F63E

Q35585366-679B8723-6537-4238-9CED-205497F24CB9

P304

Q35585366-F0270685-0C29-427B-AED1-CFEB98FF6B59

P31

Q35585366-F151BD51-67EA-4B46-92CE-2BCBE4F00254

P356

Q35585366-C2A092A0-E6DB-4B55-9462-63D25C185BBC

P433

Q35585366-4BB2EC87-3F7C-42E9-88A4-1FE5D1804CC8

P478

Q35585366-39B65B02-7B7B-48FE-928D-E364B7D5DC09

P50

Q35585366-F3A69EE6-68AF-4B0E-B134-143324568986

P577

Q35585366-F64B2A95-EFAB-4F66-BB4D-3445CDD364CB

P5875

Q35585366-6E624201-8DA1-46D9-8796-453D6A615A01

P698

Q35585366-DE24000E-E927-4EB3-8D82-1BC116C8F772

P921

Q35585366-2011DA31-BC38-4B03-823C-167B6BF3563D

Q35585366-6F0AE6C5-B24B-497A-9A56-5079AFE91B89

P932

Q35585366-DBD7FF48-7388-44E4-9C20-42093C9DA935

P356

J.JNEUROIM.2006.06.029

P1433

Journal of Neuroimmunology

P1476

Rituximab reduces B cells and ...... of multiple sclerosis patients

@en

P2093

Jennifer L Stark

http://www.w3.org/2001/XMLSchema#string

Jeri-Anne Lyons

http://www.w3.org/2001/XMLSchema#string

Joanne Lauber

http://www.w3.org/2001/XMLSchema#string

Michael J Ramsbottom

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

A study of oligoclonal band negative multiple sclerosis.

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

B cells and antibodies in CNS demyelinating disease.

Role of C5a in inflammatory responses.

Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis.

Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells.

The expression of potency of neutralizing antibodies for interferons and other cytokines.

Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies.

P304

63-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JNEUROIM.2006.06.029

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6882215

http://www.w3.org/2001/XMLSchema#string

P698

16904756

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

multiple sclerosis

P932

1769354

http://www.w3.org/2001/XMLSchema#string